- Home
- MXCT vs LXRX Comparison
MXCT vs LXRX Comparison
Compare MXCT & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- LXRX
- Stock Information
- Founded
- MXCT 1999
- LXRX 1995
- Country
- MXCT United States
- LXRX United States
- Employees
- MXCT N/A
- LXRX N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- LXRX Health Care
- Exchange
- MXCT Nasdaq
- LXRX Nasdaq
- Market Cap
- MXCT 239.2M
- LXRX 228.8M
- IPO Year
- MXCT 2021
- LXRX 2000
- Fundamental
- Price
- MXCT $2.20
- LXRX $0.92
- Analyst Decision
- MXCT Strong Buy
- LXRX Buy
- Analyst Count
- MXCT 1
- LXRX 4
- Target Price
- MXCT $9.00
- LXRX $3.67
- AVG Volume (30 Days)
- MXCT 874.5K
- LXRX 5.1M
- Earning Date
- MXCT 08-05-2025
- LXRX 07-31-2025
- Dividend Yield
- MXCT N/A
- LXRX N/A
- EPS Growth
- MXCT N/A
- LXRX N/A
- EPS
- MXCT N/A
- LXRX N/A
- Revenue
- MXCT $37,675,000.00
- LXRX $31,213,000.00
- Revenue This Year
- MXCT $8.82
- LXRX N/A
- Revenue Next Year
- MXCT $21.12
- LXRX N/A
- P/E Ratio
- MXCT N/A
- LXRX N/A
- Revenue Growth
- MXCT N/A
- LXRX 1251.21
- 52 Week Low
- MXCT $2.00
- LXRX $0.28
- 52 Week High
- MXCT $5.20
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- MXCT 51.61
- LXRX 75.98
- Support Level
- MXCT $2.00
- LXRX $0.64
- Resistance Level
- MXCT $2.28
- LXRX $0.77
- Average True Range (ATR)
- MXCT 0.12
- LXRX 0.06
- MACD
- MXCT 0.02
- LXRX 0.02
- Stochastic Oscillator
- MXCT 78.95
- LXRX 96.82
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.